Endonovo Therapeutics, Inc. ENDV

ENDV Company Overview

Endonovo Therapeutics, Inc. (OTC: ENDV) is a U.S.-based biotechnology and medical technology company focused on the development of non-invasive therapeutic devices and regenerative medicine technologies. Public disclosures indicate that the company has historically operated in the bioelectronics, electroceutical therapy, and immunotherapy sectors, with an emphasis on treatments designed to reduce inflammation, accelerate healing, and support recovery from chronic medical conditions. The company’s business activities have centered on commercializing medical devices that use electromagnetic or pulsed-field technologies for therapeutic applications.

The company’s primary revenue and development focus has historically involved its electroceutical platform technologies, including the SofPulse device platform, which has been marketed for post-operative pain management and tissue healing applications. Endonovo has also publicly discussed initiatives involving stem-cell-related therapeutics and inflammatory disease research. The company has targeted healthcare providers, rehabilitation markets, and patients requiring post-surgical recovery support. Based on available public filings and disclosures, Endonovo’s strategic positioning has relied on pursuing lower-risk medical device commercialization pathways relative to traditional pharmaceutical development. Some historical product development timelines and commercialization objectives have changed over time, and certain operational details remain limited in recent public disclosures.